We determined the effect of Prostataplex in men with lower urinary tract symptoms associated with benign prostatic hyperplasia.
A total of 92 Chinese men between 49 and 75 years old with lower urinary tract symptoms were randomly assigned in this double-blind, placebo controlled trial. The 46 patients in the intervention group were given 2 Prostataplex soft gels daily for 12 weeks, while the 46 in the control group were given 2 placebo soft gels for the same time.
The treated and control groups appeared to have more than a 95% compliance rate, as judged by counting the remaining pills in the bottle collected at the end of trial months 1 to 3. After 12 weeks of intervention the mean +/- SD maximum urinary flow rate was significantly higher in the treatment group than in the control group (14.07 +/- 2.56 vs 11.74 +/- 1.23 ml per second, p <0.001), while relative urinary resistance was significantly lower in the treatment group than in the control group (2.35 +/- 0.83 vs 3.02 +/- 1.18, p = 0.002). While there was no significant difference in mean prostate volume or International Prostate Symptom Score between the 2 groups, 18 of 46 patients (39.1%) in the treatment group showed an International Prostate Symptom Score improvement (decrease of 3 or greater) after intervention, whereas only 1 of 46 (2.2%) in the control group showed an International Prostate Symptom Score improvement (chi-square test p <0.001).
Prostataplex may have short-term effects in improving symptoms and objective measures in Chinese men with lower urinary tract symptoms associated with benign prostatic hyperplasia.
"IPSS is an 8-question written screening tool used to rapidly diagnose and suggest management of the symptoms of BPH. Patients answer 7 symptom questions, each assigning a score from 1 to 5 for a total maximum of 35 points, and a detailed description can be found in our previous publication . A higher score indicates the severity of the disease. "
[Show abstract][Hide abstract] ABSTRACT: Many cultures have used plants to treat medical affections and a percentage of modern medicines are obtained from plants. Today, several herbals have been screened for anticancer activity and many patients with cancer take plant extracts in addition to chemotherapy. This review offers an overview of the knowledge about the use of herbals and derivatives as a viable anticancer alternative therapy and their interactions (particularly, modulation of P-450 system and P-glycoprotein) with conventional anti-cancer drugs. It is suggested that health care professionals and patients should be aware of the potential for adverse interactions of this products with the anti-cancer drugs.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.